Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Clinical trial NCT03402659 · COMPLETED
Trial details
- NCT number
- NCT03402659
- Sponsor
- EIP Pharma Inc
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-29
- Primary completion
- 2019-06-30
- Enrollment
- 161
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.